B7h3-targeting car-t cell and Anti-tumor use thereof

By constructing CAR-T cells targeting B7-H3, the problem of target selection in the treatment of AML and ESCC has been solved, achieving effective killing and safe treatment of these tumor cells, demonstrating the application prospects of B7-H3 CAR-T cells.

WO2026026852A1PCT designated stage Publication Date: 2026-02-05ZHENGZHOU UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/111489
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-07-31
Filing Date
2025-07-30
Publication Date
2026-02-05

AI Technical Summary

Technical Problem

Existing CAR-T cell therapies face challenges in target selection for treating solid tumors such as acute myeloid leukemia (AML) and esophageal squamous cell carcinoma (ESCC), and existing CAR-T therapies targeting CD33 and CD123 may have toxic side effects on normal bone marrow cells, resulting in a lack of safe and effective treatment options.

Method used

We developed CAR-T cells targeting B7-H3 by constructing a CAR vector using a humanized A172 antibody, preparing CAR-T cells expressing the B7-H3 specific receptor, and conducting in vitro and in vivo experiments using lentiviral infection to evaluate their inhibitory effects on AML and ESCC cells.

Benefits of technology

It effectively kills AML and ESCC cells, showing good therapeutic potential and promising to improve the survival rate of patients with tumors that highly express B7-H3. It is also relatively safe and does not affect normal hematopoietic tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2025111489-FTAPPB-I100001
    Figure PCTCN2025111489-FTAPPB-I100001
  • Figure PCTCN2025111489-FTAPPB-I100002
    Figure PCTCN2025111489-FTAPPB-I100002
  • Figure PCTCN2025111489-FTAPPB-I100003
    Figure PCTCN2025111489-FTAPPB-I100003
Patent Text Reader

Abstract

Provided in the present invention is an isolated recombinant nucleic acid molecule, encoding a chimeric antigen receptor (CAR) polypeptide containing a single-chain antibody (scFv) targeting a B7-H3 polypeptide. Further provided are a recombinant vector containing the recombinant nucleic acid molecule, a recombinant T lymphocyte expressing the CAR polypeptide, a method for preparing the recombinant T lymphocyte, a drug for treating cancers that contains the recombinant nucleic acid molecule, recombinant vector, and recombinant T lymphocyte, and the use of the recombinant nucleic acid molecule, recombinant vector, and recombinant T lymphocyte in the treatment of cancers.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-B7-H3 monoclonal antibody and application thereof in cell therapy

    CN114957475A

  • Fully human antibody for human b7h3, chimeric antigen receptor and uses thereof

    US20240245771A1

  • Antibody targeting b7-h3 and use thereof

    WO2024001470A1